USPTO serial 86842067
ZEALAND PHARMA A/S
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 30, 2018
- Examiner
- KEELEY, ALISON REBECCA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.
Need help with ZEALAND PHARMA A/S?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Davis Graham & Stubbs LLP3400 Walnut Street, Suite 700Denver, CO 80205United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [(Based on Section 44(e)) Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for clinical or medical laboratory use; peptide substrates used in analyzing and detecting certain toxins for laboratory or research use] | SECTION 8 - CANCELLED | — |
| 005 | (Based on Section 44(e)) Pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans and animals, namely, endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, skin disorders; chemical preparations for medical and pharmaceutical purposes, namely, for the treatment of diseases, illnesses and ailments in humans and animals, namely, endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, skin disorders; first aid kits; diagnostic kits comprised of pharmaceutical and chemical preparations for the treatment of diseases, illnesses, and ailments in humans and animals, namely, endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, skin disorders | ACTIVE | — |
| 042 | [(Based on Section 44(e)) Scientific and technological services and research and design relating thereto in the field of medicine, pharmaceuticals, genetics, biology and biotechnology, namely, research, design of peptides and pharmaceutical drugs, medical and scientific laboratory services, scientific and medical research consulting services, and medical research, analysis and testing in the field of diseases, illnesses and ailments in humans and animals for scientific and research purposes, namely, in the fields of endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, and skin disorders; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; design and development of computer hardware and software; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services, namely, the development of medicines for the treatment of diseases, illnesses and ailments in humans and animals, namely, endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, skin disorders; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid, namely, information and consultancy services relating to the development of medicines for the treatment of diseases, illnesses and ailments in humans and animals, namely, endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, skin disorders] | SECTION 8 - CANCELLED | — |
| 044 | [(Based on Section 44(e)) Medical services; veterinary services; hygienic and beauty care for human beings or animals; horticulture services; dentistry services; medical analysis of peptide based medicines for the diagnosis and treatment of persons; pharmaceutical advice; medical consulting services in the field of diseases, illnesses and ailments in humans and animals, namely, endocrine disorders, nutritional and metabolic diseases, immunity disorders, blood disorders, disorders of the nervous system and sensory organs, musculoskeletal system disorders, connective tissue disorders, circulatory system disorders, respiratory system disorders, digestive system and genitourinary system disorders, skin disorders] | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Zealand Pharma A/S
- Other trademarks owned by Zealand Pharma A/S
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ZEALAND PHARMA A/S
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 28, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 28, 2025 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Aug 28, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 28, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 28, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 28, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 28, 2025 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Jul 28, 2025 | 8.PR | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | — |
| Apr 21, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 22, 2024 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Oct 30, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jun 23, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 4, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Nov 23, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 23, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 23, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 23, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 23, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 23, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 30, 2018 | R.SR | REGISTERED-SUPPLEMENTAL REGISTER | Your mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application. |
| Sep 25, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 25, 2018 | CNTA | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | — |
| Sep 24, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 24, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 24, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| May 29, 2018 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| May 29, 2018 | GNSF | SUBSEQUENT FINAL EMAILED | — |
| May 29, 2018 | CFRC | SUBSEQUENT FINAL REFUSAL WRITTEN | — |
| May 8, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 6, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 5, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 5, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2017 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 21, 2017 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Nov 21, 2017 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 27, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 23, 2017 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 28, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 28, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 28, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 6, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 6, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 6, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2017 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 23, 2017 | ALIE | ASSIGNED TO LIE | — |
| Dec 29, 2016 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Oct 7, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 7, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 7, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 16, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 16, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 16, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 16, 2016 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Mar 30, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 11, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 11, 2015 | NWAP | NEW APPLICATION ENTERED | — |